A 31-year-old regularly menstruating Japanese female was referred to our outpatient clinic by a psychiatrist. She had been diagnosed as having gender identity disorder by detailed counseling and clinical intervention 3 years earlier.
ELEVATED androgen levels are followed by the development of male physical characteristics and muscle size, structure, and function [1] . Android women also have higher bone mineral density (BMD) and upper body fat distribution, as observed in men [2] . Higher serum androgen levels contribute to upper body fat distribution [2] . Androgens have been used to increase muscle size and strength. However, it remains unclear as to whether changes in these anthropometries and BMD during androgen therapy occur simultaneously, because previous reports were based on relatively long-term testosterone therapy [3, 4] .
In this case report, we treated a female with gender identity disorder using testosterone. Changes in lean body mass, body fat mass, body fat distribution, and regional BMD during testosterone therapy are discussed.
Case description
In October 2001, a 31-year-old regularly menstruating Japanese female with right side-dominance was referred to our outpatient clinic by a psychiatrist. She had been diagnosed as having gender identity disorder by detailed counseling and clinical intervention 3 years earlier at the Department of Psychiatry, Faculty of Medicine, Kagoshima University, and Saitama Medical Center, Saitama Medical School. She was seeking androgen therapy to develop male physical characteristics and structure. The patient weighed 3120 g at birth and measured 50.5 cm after full-term gestation. Her growth and development had proceeded uneventfully in the past. She experienced menarche at the age of 12 years old. At an initial visit to our clinic, her height and weight were 160 cm and 58.0 kg, respectively. Although pubic hair development was consistent with Tanner classification IV, the breasts had been surgically removed two years earlier. External genitalia showed a normal female appearance. The presence of a vagina was confirmed by specular examination. Bimanual examination, transvaginal ultra-sonographic tomography, and magnetic resonance imaging showed normal uterine corpus and cervix. The karyotype of chromosomes was 46, XX. Several hormone levels were measured by commercially available RIA kits. At the early follicular phase, serum LH and FSH levels were 7.3 mIU/mL (normal female value) and 8.0 mIU/mL (normal female value), respectively. Serum testosterone and estradiol levels were 28 ng/dL (normal female value) and 44 pg/mL (normal female values), respectively. By medical and clinical examinations, she was deemed in apparent good health except for having gender identity disorder.
Testosterone administration to this patient was approved by the Gender Clinic Committee at Saitama Medical Center, Saitama Medical School. The study was also conducted in accordance with the provisions of the Declaration of Helsinki. After obtaining fully informed written consent, we treated her with 125 mg of testosterone enanthate (Testoviron-Depot, Nihon Schering K.K., Osaka, Japan), intramuscularly, every 2 weeks for 4 months. Before and 4 months after testosterone administration, anthropometry and regional BMD were measured by dual-energy x-ray absorptiometry (DEXA) (QDR 2000, Waltham, MA, USA). Trunk-leg fat ratio, an index of body fat distribution, was assessed by DEXA. BMD of the bilateral arms, lumbar spine (L2-4), pelvis, bilateral legs, and total body were also measured by DEXA. DEXA measurements were performed with a total body scanner and results were evaluated by the same examiner. Table 1 presents changes in baseline characteristics, anthropometric characteristics, and BMD after 4 months of testosterone therapy. During the observation period, there were no changes in life style, daily physical activity, or food intake. Serum testosterone levels increased to the normal male value (from 28 to 432 ng/dL). Although the menstrual cycle remained regular, her voice became lower after 4 months of therapy. Body weight, body mass index (BMI), and lean body mass increased (from 58.0 to 60.6 kg, 22.7 to 23.7, and 35.4 to 39.8 kg, respectively), while body fat mass and percentage of body fat decreased (from 20.6 to 18.0 kg and 35.6 to 31.1%, respectively). However, trunk-leg fat ratio and regional bone mineral density (BMD) did not change during the observation period (trunk-leg fat ratio, from 0.881 to 0.887).
Discussion
The serum testosterone level increased after 4 months of testosterone enanthate administration in a female with gender identity disorder. However, increased testosterone levels did not disturb ovulation. We found that lean body mass markedly increased while body fat mass markedly decreased during testosterone therapy. Our observation agrees with the report by Bruce et al. [4] , indicating that danazol, 17-a-ethinyl testosterone, disproportionately increases lean body mass and decreases body fat mass in patients with endometriosis. Although this case is not completely analogous to the hormonal background of androgenic polycystic ovary syndrome (PCOS), this case has some implications for anthropometry in patients with PCOS. PCOS, one of the most common endocrine disorders, involves chronic anovulation, hyperandrogenism, insulin resistance, and obesity. Obesity is defined as excess body fat mass. Obesity has been conventionally assessed by BMI. However, BMI does not always reflect overall adiposity, and it rather reflects frame size. In this case, BMI increased despite decreases in the percentage of body fat and body fat mass during testosterone therapy. Thus, it is speculated that not overall adiposity but greater lean body mass is characteristic of androgenic PCOS patients. It has been suggested that there is a tendency toward a decreased percentage of body fat (i.e., increase in percentage of lean body mass) in lean patients with androgenic PCOS [5] . To confirm this speculation, it is necessary to compare anthropometry between PCOS patients and age-and BMI-matched controls.
Testosterone increases muscle fibers. It is of interest whether the increase in muscle size during testosterone therapy occurs uniformly at various sites of the segmental regions. In this case, lean mass of the dominant arm markedly increased compared to that of the nondominant arm. Elbers et al. [3] reported that muscle area at the thigh level increased significantly by 12.6 ± 7.6% from the baseline one year after administration of testosterone in young female-to-male transsexuals. Postmenopausal women treated with androgen for 9 months gained muscle mass despite overall weight loss, and this result was mainly attributable to a significant increase in the midthigh muscle area [6] . Trunk-leg lean ratio in the report by Bruce et al. [4] significantly decreased 6 months after danazol therapy. In these three studies, unfortunately, arm muscle area was not examined. Muscle mass is also influenced by physical exercise. Naturally, physical exercise in daily life is greater in the arms than in the trunk. Thus, it is plausible that a higher testosterone level causes a greater muscle mass deposit in the arms than in the trunk [7] .
To clarify changes toward upper body fat distribution during testosterone therapy, our own data on longer-term testosterone therapy may be optimal. However, there is an established concept that longterm testosterone administration is associated with upper body fat distribution and higher BMD [3, 5, 8] . Androgenic environment is associated with upper body fat distribution, indicative of excess abdominal visceral fat mass [1] . Testosterone inhibits femoral lipoprotein lipase activity [8] . Elbers et al. [3] reported that one-year administration of testosterone in young, nonobese female subjects increased the amount of visceral fat. Even slender androgenic women with PCOS had higher arm BMD than controls due to local mechanical action [5] . In this case, however, neither body fat distribution nor regional BMD had changed 4 months after testosterone therapy. Body fat distribution remained the female type. Thus, there was no significant change in body fat distribution and BMD attributable to short-term testosterone administration.
During testosterone therapy, a disproportionate increase in lean body mass and decrease in body fat mass may be early onset events, while the shift toward upper body fat distribution may be a late onset event along with increase in BMD.
